About
Sentaur Bio is a biotech company with a focus on senescence biology that discovers and develops breakthrough treatments for debilitating age-related diseases.
Sentaur’s library of distinct senescent cell surface proteins discovered by high throughput proteomic analysis, was licensed from the laboratory of Prof. Valery Krizhanovsky, an Associate Professor at the Weizmann Institute of Science and a world-renowned expert in senescence. By leveraging its powerful library platform of distinct cell surface proteins, Sentaur’s mission is to treat diseases involving senescent cells burden, with primary focus in oncology and in the future debilitating age-related diseases.
The company also aims to leverage its platform to continue discovering and developing surface markers of senescence by strategic partnering.
Funding history · 3 rounds · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of Sentaur Biosciences?
- Sentaur Biosciences is currently inactive, having ceased operations in March 2024.
- When was Sentaur Biosciences founded and what was its initial focus?
- Sentaur Biosciences was founded in March 2018 as EXPLORE BIO 3, focusing on senescence biology to develop treatments for age-related diseases.
- From whom did Sentaur Biosciences license its library of senescent cell surface proteins?
- Sentaur Biosciences licensed its library of distinct senescent cell surface proteins from the laboratory of Prof. Valery Krizhanovsky, an Associate Professor at the Weizmann Institute of Science.
- What was the primary therapeutic area Sentaur Biosciences aimed to address?
- Sentaur Biosciences' primary therapeutic focus was oncology, with future plans to address debilitating age-related diseases involving senescent cells.
- Which investors participated in Sentaur Biosciences' initial Seed funding round in June 2018?
- In June 2018, Sentaur Biosciences received Seed funding from M Ventures and ExploreBio.
- When did Sentaur Biosciences secure its latest known funding round?
- Sentaur Biosciences secured its latest known Seed funding round in July 2023, with M Ventures as an investor.
- What was the employee count for Sentaur Biosciences?
- Sentaur Biosciences had an employee count of 3.
- What was the name of one of Sentaur Biosciences' products in development?
- One of Sentaur Biosciences' products in development was SB101.